Researcher Spotlight: Neha Mehta-Shah, MD
Washington University in Saint Louis
Dr. Mehta-Shah is Assistant Professor at the Washington University School of Medicine in Saint Louis. Her Lymphoma Clinical Research Mentoring Program (LCRMP) project seeks to develop a method for identifying residual disease in peripheral A type of white blood cell that participates in immune responses by destroying harmful substances or cells. lymphomas (PTCL). PTCL is a group of rare lymphomas most commonly treated with Several drugs given together to increase response rate of certain tumors. A type of Spongy material found inside the bones containing stem cells that develop into three types of cells: red blood cells that deliver oxygen to the body and take away carbon dioxide; white blood cells that protect the body from infection; and platelets or stem cell transplantation in which a patient receives his or her own cells. stem cell transplant. However, it is often difficult to identify the patients who will most benefit from transplant after therapy, as residual lymphoma cells can be difficult to detect via Computed tomography (CT). This imaging test provides a series of detailed picutres of inside the body using an X-ray machine linked to a computer. (computerized tomography) or A test that evaluates metabolic activity in different parts of the body using radioisotope. scans. Dr. Mehta-Shah and her collaborators are evaluating two methods for testing patient blood samples to detect these residual PTCL cells. “Patients with these rare diseases suffer from our lack of knowledge regarding how to tailor treatment to specific disease types,” Dr. Mehta-Shah says. “These techniques may also be used to develop liquid biopsies for mutational profiling of tumors or serve as a method to help us determine which patients are more likely to A disease that reappears or grows again after a period of The absence of disease. Remission does not necessarily indicate that a person is cured. Patients may have complete or partial remission.. from these Lymphomas that are fast growing and generally need to be treated immediately. Also called intermediate-grade or high-grade lymphomas..”
Dr. Mehta-Shah says that “she was one of those kids who knew she wanted to be a doctor in elementary school,” following in the footsteps of her mother, a pediatrician. “Then, in high school, I spent time with a pediatric A physician who specializes in treating diseases of the blood and blood forming tissues./oncologist and became involved in laboratory research. After that, I realized I wanted to pursue a career in academic oncology.” She received her MD from Northwestern University’s Feinberg School of Medicine, where she became acquainted with Steven Rosen, MD and his research on cutaneous T-cell lymphoma. She completed her residency and fellowship at Memorial Sloan Kettering Abnormal cell growth that cannot be controlled by the body's natural defenses. Cancerous cells can grow and eventually form tumors. Center under the direction of Steven Horwitz, MD before moving to Washington University. “Steve [Horowitz] taught me to think critically, doctor compassionately, lead gracefully, and reach for the stars,” she notes.
Dr. Mehta-Shah hopes to develop her career to become a leader in clinical research efforts to improve treatment for patients, as well as teach and mentor others. She sees her participation in the LCRMP as a step forward in this development. “Improving our knowledge about lymphoma from all fronts is critical to advancing the field. I anticipate that the mentorship that the Workshop will provide will be equally valuable to my success.” She adds that, ultimately, her patients provide the greatest inspiration to continue her work. “They are the reason we do all of this research. I hope that in my lifetime I can see them reap the benefits of the efforts of our research community.”